Lenzetto (Estradiol)

Lenzetto provides estrogen replacement through the transdermal route, addressing conditions related to low endogenous estrogen.

• Menopausal symptoms: reduces hot flashes, night sweats and improves mood.
• Estrogen deficiency: restores systemic estrogen levels and alleviates associated vasomotor disturbances.
• Hypoestrogenism: supports bone health and urogenital tissue integrity in women with low estrogen production.

• Estradiol in Lenzetto acts as an agonist at estrogen receptors (ERα and ERβ) in target tissues. Binding triggers transcriptional regulation of estrogen‑responsive genes, leading to restoration of normal hormonal signaling pathways that control vasomotor regulation, bone remodeling, and urogenital tissue maintenance.

Common Side Effects

• Skin irritation at the application site: redness or itching where the patch is applied.
• Headache: mild to moderate intensity.
• Nausea: occasional upset stomach.
• Breast tenderness: mild discomfort or swelling.
• Mood changes: fluctuations in emotional state.
• Fluid retention: mild swelling of ankles or feet.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Stroke: cerebrovascular accident risk.
• Myocardial infarction: heart attack.
• Hepatotoxicity: liver enzyme elevation.
• Endometrial hyperplasia: abnormal uterine lining growth.
• Gallbladder disease: biliary colic or cholecystitis.

Before initiating therapy, consider patient‑specific risk factors and monitor appropriately.

• Assess cardiovascular risk: evaluate history of clotting disorders or thrombosis.
• Monitor breast changes: report any new lumps or discharge.
• Consider bone health: assess osteoporosis risk in long‑term use.
• Avoid use in active liver disease: contraindicated in severe hepatic impairment.
• Pregnancy and lactation: not recommended due to unknown safety.
• Store at room temperature: keep in the original pouch, protect from light and moisture.

Estradiol may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Combined estrogen therapy (e.g., oral contraceptives): increased thrombotic risk.
• Tamoxifen: antagonistic effect reducing therapeutic benefit.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower estradiol levels.
• Azole antifungals (e.g., ketoconazole): can raise estradiol concentrations.
• Anticoagulants (e.g., warfarin): may enhance anticoagulant effect.

Moderate Interactions (Monitor Closely)

• SSRIs (especially fluoxetine, paroxetine): may diminish hot‑flash relief.
• Antihypertensives: monitor blood pressure for potential changes.
• Thyroid hormone replacement: assess thyroid function periodically.
• Antidiabetic agents: observe glucose control as estrogen can affect insulin sensitivity.